Skip to main content
Premium Trial:

Request an Annual Quote

Georg Casari, Claire Fraser

Premium

Georg Casari has joined Oridis Biomed, a developer of therapeutics for liver cancer and metabolic liver disease, as chief information officer. Casari was previously vice president of informatics at Cellzome and a co-founder of Lion Bioscience, where he served as senior vice president of life science informatics. Prior to that, he was a staff scientist at the European Molecular Biology Laboratory and the European Bioinformatics Institute. In his new position, Casari will be responsible for Oridis' data integration and information management.


The American Society for Microbiology has granted Claire Fraser, president and director of the Institute for Genomic Research, the Promega Biotechnology Research Award. Fraser received the award last week at ASM's general meeting in Atlanta. She was honored for her "outstanding contributions and research to the application of biotechnology through fundamental microbiological research and development." The award is administered by ASM and sponsored by Promega.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.